PRAVACHOL Drug Patent Profile

When do Pravachol patents expire, and when can generic versions of Pravachol launch?

Pravachol is a drug marketed by Bristol Myers Squibb and is included in one NDA.

The generic ingredient in PRAVACHOL is pravastatin sodium. There are sixteen drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the pravastatin sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Pravachol

A generic version of PRAVACHOL was approved as pravastatin sodium by AUROBINDO PHARMA USA on April 24^th, 2006.

Summary for PRAVACHOL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	67
Clinical Trials:	28
Patent Applications:	7,172
Drug Prices:	Drug price information for PRAVACHOL
Drug Sales Revenues:	Drug sales revenues for PRAVACHOL
What excipients (inactive ingredients) are in PRAVACHOL?	PRAVACHOL excipients list
DailyMed Link:	PRAVACHOL at DailyMed

See drug prices for PRAVACHOL

See drug sales revenues for PRAVACHOL

Recent Clinical Trials for PRAVACHOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Brigham and Women's Hospital	Phase 4
Amgen	Phase 4
Mayo Clinic	Phase 2

See all PRAVACHOL clinical trials

Paragraph IV (Patent) Challenges for PRAVACHOL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PRAVACHOL	Tablets	pravastatin sodium	30 mg	019898	1	2005-06-01

US Patents and Regulatory Information for PRAVACHOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	PRAVACHOL	pravastatin sodium	TABLET;ORAL	019898-002	Oct 31, 1991		DISCN	Yes	No
Bristol Myers Squibb	PRAVACHOL	pravastatin sodium	TABLET;ORAL	019898-008	Dec 18, 2001		DISCN	Yes	No
Bristol Myers Squibb	PRAVACHOL	pravastatin sodium	TABLET;ORAL	019898-003	Oct 31, 1991		DISCN	Yes	No

Expired US Patents for PRAVACHOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bristol Myers Squibb	PRAVACHOL	pravastatin sodium	TABLET;ORAL	019898-008	Dec 18, 2001	5,622,985*PED
Bristol Myers Squibb	PRAVACHOL	pravastatin sodium	TABLET;ORAL	019898-004	Mar 22, 1993	5,622,985*PED
Bristol Myers Squibb	PRAVACHOL	pravastatin sodium	TABLET;ORAL	019898-002	Oct 31, 1991	4,346,227*PED

International Patents for PRAVACHOL

See the table below for patents covering PRAVACHOL around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	79030
Denmark	0738512
Ireland	911910

Market Dynamics and Financial Trajectory for Pravachol (Pravastatin)

Last updated: February 20, 2026

What is the Current Market Position of Pravachol?

Pravachol (pravastatin sodium) is a statin medication used to lower LDL cholesterol and reduce cardiovascular risk. Launched by Bristol-Myers Squibb in 1986 and acquired by Sanofi in 2005, it faced stiff competition from newer statins such as atorvastatin and rosuvastatin.

Annual global sales peaked near $500 million in the late 2000s. Since then, market penetration declined due to the emergence of more potent, once-daily, and fixed-dose combination therapies dominating the statin segment.

How Has the Patent and Regulatory Status Affected Its Market?

Pravachol’s original patent expired in the US in 2006, with subsequent generic versions entering the market shortly after. In multiple countries, including the US, generic pravastatin became widely available by 2007.

This patent expiration reduced the drug’s market share and pricing power. Bristol-Myers Squibb withdrew Pravachol from numerous markets in the early 2010s, and Sanofi announced discontinuation in some regions. Currently, pravastatin generics constitute a significant portion of prescribed statins in established markets.

In the US, pravastatin’s regulatory approval dates to February 1991. The drug remains on the formulary as a cost-effective alternative but faces decreasing prescribing rates compared to high-potency statins and PCSK9 inhibitors.

What Are the Key Market Forces Influencing Pravachol?

Competitive Landscape

Pravachol faces competition primarily from atorvastatin (Lipitor), rosuvastatin (Crestor), and simvastatin (Zocor). Lipitor, launched in 1997, achieved peak sales of over $12 billion in 2006, overshadowing pravastatin’s revenues.

The rise of high-intensity statins, which achieves LDL reductions of over 50%, diminishes pravastatin’s appeal, especially for high-risk patients. Additionally, PCSK9 inhibitors (e.g., evolocumab, alirocumab) offer injectable alternatives with LDL reductions exceeding 60%, impacting the entire statin market.

Pricing and Reimbursement

Generic pravastatin prices in the US target a $0.05-$0.10 per pill range. Payers favor generics for cost controls, further limiting pravachol’s market share. In lower-income regions, pravastatin remains a primary therapy due to affordability.

Prescribing Trends

Physician preferences shift toward high-potency statins or combination therapies. Clinical guidelines emphasize intensity of LDL reduction, favoring drugs like atorvastatin and rosuvastatin.

What Is the Financial Trajectory for Pravachol Moving Forward?

Revenue Outlook

Based on current generics market share, pravastatin generics generate approximately $200-$300 million annually globally. Several factors influence this volume:

• Market Saturation: Mature markets exhibit stagnant or declining prescription volumes.
• Pricing Pressure: Continuous competition keeps prices low, limiting revenue growth.
• Regulatory Environment: Generic proliferation in developed countries constrains margins.

Growth Opportunities

Limited growth is expected in traditional markets due to patent expiration and competition. Emerging markets present potential due to larger populations with unmet needs and less access to high-end therapies. However, local price controls and regulatory barriers pose challenges.

Pipeline and Formulation Developments

No new formulations or pipeline developments for pravastatin are currently under active consideration. Sanofi and other manufacturers focus on novel lipid-lowering agents or combination therapies with better efficacy or adherence profiles.

How Do Regulatory Policies Impact Market Dynamics?

Regulatory agencies, including the FDA and EMA, emphasize clinical benefits over cost when approving new statins and lipid-lowering agents. This shift favors newer drugs with superior efficacy, further reducing pravastatin’s market share.

In developed markets, payers often require prior authorization and impose formulary restrictions favoring high-potency statins and PCSK9 inhibitors. Reimbursement for older, less potent drugs like pravastatin decreases accordingly.

What Are the Key Financial Metrics?

Metric	Data (Approximate)
Peak Annual Sales	~$500 million (2008)
Estimated Current Market Share	10-15% of statin market
Annual Revenue (Global)	$200-$300 million
Gross Margin (Generic Sales)	~80%
Market Growth Rate (Next 5 years)	Negative to stagnant

Conclusions

Pravachol faces a declining market trajectory driven by patent expiration, competition from potent statins, and evolving treatment guidelines emphasizing high-intensity therapy and novel agents. Its sales are expected to remain stable or decline modestly, with growth opportunities primarily in emerging markets.

Key Takeaways

• Pravachol’s market share has decreased significantly since patent expiration in 2006.
• Generic pravastatin remains a low-cost option but faces stiff competition from higher-potency statins.
• The drug's future depends on market demand in developing countries and formulary positioning.
• New formulations or therapeutic indications are unlikely; focus remains on existing generics.
• The overall market trend favors newer, more effective LDL-lowering therapies over pravastatin.

FAQs

1. Why did Pravachol lose market share?
Patent expiration in 2006 facilitated widespread generic entry, resulting in price competition and declining revenues.

2. Are there any new formulations for Pravachol?
No, there are no new formulations or extension programs currently under development.

3. How does Pravachol compare to other statins in efficacy?
Pravastatin achieves LDL reduction of approximately 30-40%, lower than high-potency statins like atorvastatin or rosuvastatin.

4. Is Pravachol used in combination therapies?
Not typically; current guidelines favor high-potency statins or PCSK9 inhibitors for combination approaches.

5. What is the outlook for Pravachol in emerging markets?
Potential exists due to affordability, but local regulations, pricing pressures, and competing local generics influence growth.

---

References

[1] U.S. Food and Drug Administration. (2023). Drug Product Label: Pravachol.
[2] IMS Health. (2010). Global Trends in Lipid-Lowering Therapy.
[3] MarketWatch. (2022). Statin Market Data and Forecast.
[4] European Medicines Agency. (2006). Market Authorization of Pravastatin.
[5] Sanofi Annual Report. (2022). Lipid-Lowering Portfolio Update.